Physician profile
John M Freeman
NPI 1538168455
$135,719.73
in general payments reported to CMS, 2019-2025
28 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $294 · 2021: $444 · 2022: $128K · 2023: $5,765 · 2024: $407 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,344 · Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,343.75 |
| Food and Beverage | $938.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grace Medical, INC. | $127,500.00 | 2022 | |
| Rxsight INC | $5,518.46 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $460.18 | 2019-2024 | Amo Phaco Needle, Tecnis Iol |
| Alcon Vision LLC | $337.63 | 2019-2024 | Clareon, Lensx, Rocklatan |
| Allergan, INC. | $278.48 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $185.43 | 2022-2024 | Xiidra, Vyzulta, Miebo |
| Abbvie INC. | $169.65 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $161.86 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $148.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $143.29 | 2019-2023 | |
| Shire North American Group INC | $116.97 | 2019 | |
| Biotissue Holdings INC. | $86.02 | 2020-2024 | |
| Oyster Point Pharma, INC. | $77.76 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $63.81 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $59.31 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.35 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $54.60 | 2024 | Vevye |
| New World Medical,INC. | $50.10 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $46.62 | 2023 | Quatera 700 |
| Ocular Therapeutix, INC. | $36.22 | 2019-2020 | |
| Dompe US, INC. | $35.80 | 2021-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $27.29 | 2024 | Xdemvy |
| Vertex Pharmaceuticals Incorporated | $21.15 | 2025 | |
| Mallinckrodt Enterprises LLC | $19.66 | 2019 | |
| Thea Pharma INC. | $18.88 | 2024 | Iyuzeh |
| Hologic Sales and Service, LLC | $18.67 | 2024 | Myosure Tissue Removal Device |
| Regeneron Healthcare Solutions, INC. | $14.17 | 2023 | Eylea |
| Eyevance Pharmaceuticals LLC | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,045,530.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.